You just read:

PharmaMar Presents the Overall Survival Data From the Phase I/II Study of lurbinectedin in Combination With Doxorubicin for Relapsed Small Cell Lung Cancer

News provided by

PharmaMar

Sep 24, 2018, 16:46 ET